Extraction form for project: Screening for Glaucoma in Adults - 1 of 2

Design Details

1. Study design

Arms

Arm NameArm Description
A. Netarsudil/Latanaprost FDCP (n=238; comparison NR)
B. Netarsudil 0.02% (n=244)
C. Latanaprost 0.005% (n=236)

Sample Characteristics

1. N
A. Netarsudil/Latanaprost FDCP (n=238; comparison NR)
B. Netarsudil 0.02% (n=244)
C. Latanaprost 0.005% (n=236)
Total
2. Baseline population
A. Netarsudil/Latanaprost FDCP (n=238; comparison NR)
B. Netarsudil 0.02% (n=244)
C. Latanaprost 0.005% (n=236)
Total

Outcomes

TypeDomainSpecific measurement (i.e., tool/definition/specific outcome)PopulationsTimepoints
CategoricalVision disorderMean intraocular pressure (IOP) reduction >20%, 12 months
  • All Participants
  • 12 months
ContinuousHarm/adverse eventWithdrawal due to adverse events
  • All Participants
  • end of study

Risk of Bias Assessment

1. Random assignment
2. Allocation concealed
3. Groups similar at baseline
4. Eligibility criteria specified
5. Blinding: outcome assessors or data analysts
6. Intention-to-treat analysis
7. Reporting of attrition, contamination, etc.
8. Differential loss to followup or overall high loss to followup
9. Appropriate analysis including cluster correlation
10. Funding source
11. Randomization adequate?
12. Allocation concealment adequate?
13. Groups similar at baseline?
14. Eligibility criteria specified?
15. Outcome assessors masked?
16. Care provider masked?
17. Patient masked?
18. Attrition and withdrawals reported?
19. Loss to followup differential/ high?
20. People analyzed in the groups in which they were randomized?
21. Quality

Results

Categorical


Vision disorder (Mean intraocular pressure (IOP) reduction >20%, 12 months)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Netarsudil/Latanaprost FDCP (n=238; comparison NR)B. Netarsudil 0.02% (n=244)C. Latanaprost 0.005% (n=236)
vs.
12 months
Percentage
Risk Ratio (RR)
95% CI low (RR)
95% CI high (RR)
Within Arm ComparisonsNet Comparisons
A. Netarsudil/Latanaprost FDCP (n=238; comparison NR)B. Netarsudil 0.02% (n=244)C. Latanaprost 0.005% (n=236)
vs.

Continuous


Harm/adverse event (Withdrawal due to adverse events)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Netarsudil/Latanaprost FDCP (n=238; comparison NR)B. Netarsudil 0.02% (n=244)C. Latanaprost 0.005% (n=236)
vs.
end of study
Percentage
Relative risk (RR) (95% CI)
Within Arm ComparisonsNet Comparisons
A. Netarsudil/Latanaprost FDCP (n=238; comparison NR)B. Netarsudil 0.02% (n=244)C. Latanaprost 0.005% (n=236)
vs.